Complement Activation and Central Nervous System Injury After Coronary Artery Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00188006|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : September 16, 2005
The impact of the postoperative inflammatory response on the central nervous system after cardiac surgery is uncertain.
The goal of this study was to evaluate the role of complement activation on cellular brain injury and neurological functioning in patients undergoing coronary artery surgery. In addition, the effect of complement activation on the cerebral vasomotricity was assessed.
Because receptors to activated complement are present on astrocytes, the heparin-coated cardiopulmonary bypass that reduces complement activation should minimize these postoperative neurological adverse events. Heparin-coating might also influence blood flow velocity in cerebral arteries postoperatively if complement activation mediates cardiopulmonary bypass induced cerebral vasomotor dysfunction.
|Condition or disease||Intervention/treatment|
|Coronary Artery Bypass Grafting||Device: heparin-coated cardiopulmonary bypass|
Closed cardiopulmonary bypass and controlled suctions of pericardial shed blood were standardized in all patients.
Bedside transcranial Doppler examination served to evaluate the development of cerebral vasomotor dysfunction in a subgroup of patients.
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Biocompatible Cardiopulmonary Bypass and Neuropsychological Outcome After Coronary Artery Bypass Surgery|
- sC5b-9 release
- s100beta release
- changes in neuropsychological functioning (z scores of cognitive domains)
- blood flow velocity in the middle cerebral artery (subgroup)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00188006
|Principal Investigator:||Christophe BAUFRETON, MD PhD||University Hospital of Angers, France|